Primary Catalyst Driving Apixaban Market Evolution in 2025: Impact Of Cardiovascular Disease Prevalence On Apixaban Market Growth Driver

What Is the Future Outlook for the Apixaban Market's Size and Growth Rate?
In the past few years, there has been significant growth in the apixaban market size. It is projected to ascend from $2.92 billion in 2024 to $3.19 billion in 2025, marking a compound annual growth rate (CAGR) of 9.2%. The growth observed in the historic period is due to factors such as the rising case of atrial fibrillation, the increase in the aging population, regulatory sanctions and expansions, positive clinical results, and the transition from warfarin to NOACs.

The apixaban market size is expected to see strong growth in the next few years. It will grow to $4.48 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to continued incidence of cardiovascular diseases, increasing awareness and diagnosis rates, expansion in emerging markets, aging global population, health policy and reimbursement changes. Major trends in the forecast period include advancements in drug delivery systems, increasing research and developments, innovation and collaborations, approval of apixaban by the FDA, digital health and telemedicine.

What Are the Forces Behind the Rapid Growth of the Apixaban Market?
The increasing incidences of heart and blood vessel diseases are anticipated to boost the apixaban market's expansion. Cardiovascular disease, which includes conditions such as coronary artery disease, stroke, and heart failure, is on the rise due to inactive lifestyles, poor nutrition, tobacco consumption, obesity, hypertension, diabetes, and an aging population. Apixaban plays a role in managing these diseases by mitigating the likelihood of blood clots and preventing conditions like stroke, deep vein thrombosis, and pulmonary embolism. As per the American Heart Association, a non-profit organization based in the US, the number of cardiovascular disease-related deaths in January 2024 was 931,578, showing a modest increase of less than 3,000 over the 928,741 recorded in 2023. Hence, the escalation in cardiovascular diseases underpins the growth in the apixaban market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15979&type=smp

Which Key Market Leaders Are Driving Apixaban Industry Growth?
Major companies operating in the apixaban market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hetero Drugs Ltd, Eisai Co. Ltd, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd, Medichem S.A., Centaur Pharmaceuticals Pvt. Ltd., Simson Pharma Limited, OPOCRIN SPA, Pinnacle Life Sciences Private Limited

What Are the Emerging Trends in the Apixaban Industry?
Major firms in the apixaban market are concentrating on the creation of revolutionary products such as generic anticoagulant medication. They aim to enhance affordability and accessibility for patients, thus broadening their market presence and competitiveness. Generic anticoagulant drugs work by interfering with various factors in the coagulation process, which reduces stroke risk and other cardiac events. For example, Tiefenbacher Pharmaceuticals, a healthcare firm from Germany, introduced a generic form of Apixaban in Canada in October 2022. This oral anticoagulant serves various thrombotic disorders and is used after elective joint replacements such as hip or knee, prevention of stroke in atrial fibrillation, as well as the treatment of deep vein thrombosis and pulmonary embolism. The company produced 2.5 mg and 5 mg anticoagulant tablets in their Indian labs, which will be marketed in Canada in tandem with other generic pharmaceutical firms, with an eventual launch planned in other global markets. This strategic decision provides substantial financial savings for international healthcare systems and increases access to critical treatments for millions of patients.

What Are the Main Segments in the Apixaban Market?
The apixaban market covered in this report is segmented -

1) By Dosage Form: Capsule, Tablets
2) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Capsule: 2.5 mg Capsule, 5 mg Capsule
2) By Tablets: 2.5 mg Tablet, 5 mg Tablet

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

Which Geographic Area Leads the Apixaban Market?
North America was the largest region in the apixaban market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apixaban market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Apixaban Global Market Report?

- Market Size Analysis: Analyze the Apixaban Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Apixaban Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Apixaban Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Apixaban Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15979

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.